TMTP1
TMTP1 is a five-amino acid (NVVRQ) tumor-homing peptide. TMTP1 slows the growth of tumor cells. TMTP1 serves as a diagnostic marker for hematological malignancies and acts as an anticancer drug carrier to enhance the cellular uptake rate of nanocarriers in tumor tissues. TMTP1 is applicable to research related to hematological malignancies, lymphoma, chronic myeloid leukemia, cervical cancer, and ovarian cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1227627-77-1
- 화학식: C25H46N10O8
- 분자량:614.69
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
TMTP1 (10-120 μM; 1 h total incubation) competitively inhibits the binding of FITC-TMTP1 to hematologic malignant cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
TMTP1 (35 μM; intravenous injection; single administration) can competitively block the tumor-targeting ability of TP-NLC, confirming that TMTP1 mediates the specific enrichment of this nanocarrier in cervical cancer xenografts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nu (female, lymphoma-bearing, tumors reached 1.5 cm3 before treatment)[1]
-
Dosage:210 μg/mouse
-
Administration:i.v.; twice a week; one month
-
Result:Significantly inhibited tumor growth.
-
Animal Model:C57BL/6 (female, 4-6 weeks old, subcutaneous xenograft model via flank injection of 2 × 105 TC-1 cells)[2]
-
Dosage:35 μM
-
Administration:i.v.; single dose
-
Result:Reduced tumor fluorescence intensity of TP-NLC to levels comparable to free ICG and non-targeted GA/ICG-NLC groups.
Chemical Information
-
CAS No. 1227627-77-1
-
분자량 614.69
-
화학식 C25H46N10O8
-
Sequence
Asn-Val-Val-Arg-Gln
-
Sequence Shortening
NVVRQ
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Xiao M, et al.. TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2011 Oct;31(5):608. [Content Brief]
[2]. Xu H, et al.. TMTP1-modified nanocarrier boosts cervical cancer immunotherapy by eliciting pyroptosis. Theranostics. 2025;15(11):5420-5439. [Content Brief]
[3]. Zhou Y, et al.. Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer. Journal of nanobiotechnology. 2024 Aug 13;22(1):483. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TMTP1 Related Classifications
HY-P11815 Related Classifications
Powered by Bioz